Pazopanib in Metastatic Renal Cancer: A “Real-World” Experience at National Cancer Institute “Fondazione G. Pascale”
- 1Division of Medical Oncology, Department of Uro-Gynaecological Oncology, Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale,” Naples, Italy
- 2Department of Onco-Ematology Medical Oncology, S.G. Moscati Hospital of Taranto, Taranto, Italy
- 3Unit of Epidemiology, Struttura Complessa di Statistica Medica, Biometria e Bioinformatica, Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale,” Naples, Italy
- 4Pharmacy Unit, Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale,” Naples, Italy
- 5Division of Urology, Department of Uro-Gynaecological Oncology, Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale,” Naples, Italy
- 6Scientific Direction, Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale,” Naples, Italy
- 7Division of Radiation Oncology, Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale,” Naples, Italy
- 8Division of Medical Oncology–Centro di Riferimento Oncologico, Aviano, Italy
- 9Oncology Unit, A.O.R.N. dei COLLI “Ospedali Monaldi-Cotugno-CTO,” Naples, Italy
A corrigendum on
Pazopanib in Metastatic Renal Cancer: A “Real-World” Experience at National Cancer Institute “Fondazione G. Pascale”
by Cecere, S. C., Rossetti, S., Cavaliere, C., Della Pepa, C., Di Napoli, M., Crispo, A., et al. (2016). Front. Pharmacol. 7:287. doi: 10.3389/fphar.2016.00287
In the original article, we have neglected to thank our funder, Novartis Farma S.p.A. The Funding Statement appears below.
Funding
Novartis Farma S.p.A. supported publication of this article.
The authors apologize for this oversight. This error does not change the scientific conclusions of the article in any way.
Conflict of Interest Statement
The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Keywords: pazopanib, metastatic renal cancer, real world, angiogenesis inhibitors, treatment
Citation: Cecere SC, Rossetti S, Cavaliere C, Della Pepa C, Di Napoli M, Crispo A, Iovane G, Piscitelli R, Sorrentino D, Ciliberto G, Maiolino P, Muto P, Perdonà S, Berretta M, Pignata S, Facchini G and D'Aniello C (2016) Corrigendum: Pazopanib in Metastatic Renal Cancer: A “Real-World” Experience at National Cancer Institute “Fondazione G. Pascale.” Front. Pharmacol. 7:468. doi: 10.3389/fphar.2016.00468
Received: 10 October 2016; Accepted: 18 November 2016;
Published: 05 December 2016.
Edited and reviewed by: Giovanni Li Volti, University of Catania, Italy
Copyright © 2016 Cecere, Rossetti, Cavaliere, Della Pepa, Di Napoli, Crispo, Iovane, Piscitelli, Sorrentino, Ciliberto, Maiolino, Muto, Perdonà, Berretta, Pignata, Facchini and D'Aniello. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Gaetano Facchini, Z2FmYWNjaGlAbGliZXJvLml0